Tolerance of bradykinin-releasing drugs in patients with acquired C1 inhibitor deficiency: a case series and review of the literature. - Université de Lille Accéder directement au contenu
Article Dans Une Revue European Journal of Dermatology Année : 2022

Tolerance of bradykinin-releasing drugs in patients with acquired C1 inhibitor deficiency: a case series and review of the literature.

Résumé

Bradykinin-mediated angioedema (AE) manifests as recurrent oedema of the mucosa, skin and abdominal wall, usually lasting 48 to 96 hours. It can be caused by bradykinin-releasing drugs (such as angiotensin converting enzyme inhibitors [ACEi], angiotensin receptor blockers [ARB] and dipeptidyl peptidase 4 inhibitors [DPP-4i]) or by C1-inhibitor (C1-INH) deficiency, which can be hereditary (HAE) or more rarely acquired (AAE). AAE is classically associated with lymphoid malignancies or monoclonal gammopathy [...]
Fichier non déposé

Dates et versions

hal-04488622 , version 1 (04-03-2024)

Identifiants

Citer

Guillaume Escure, Morgane Nudel, Louis Terriou, Meryem-Maud Farhat, David Launay, et al.. Tolerance of bradykinin-releasing drugs in patients with acquired C1 inhibitor deficiency: a case series and review of the literature.. European Journal of Dermatology, 2022, European Journal of Dermatology, 32, pp.49-55. ⟨10.1684/ejd.2021.4175⟩. ⟨hal-04488622⟩

Collections

RIIP UNIV-LILLE
5 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More